Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluoxetine + repetitive transcranial magnetic stimulation
- Development stage
- Unknown
- Lead developer
- Spaulding Rehabilitation Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fluoxetine combined with repetitive transcranial magnetic stimulation (rTMS) is an experimental therapeutic approach being evaluated for motor recovery following ischemic stroke. Fluoxetine is a small molecule selective serotonin reuptake inhibitor (SSRI) that inhibits the serotonin transporter (SERT), potentially enhancing neuroplasticity and neurogenesis. In this combination therapy, 1-Hz low-frequency rTMS is applied to the contralesional (unaffected) primary motor cortex to downregulate its excitability, aiming to balance interhemispheric inhibition and facilitate motor function in the paretic limb. This specific protocol was investigated in a Phase 2 clinical trial (NCT02208466) led by Spaulding Rehabilitation Hospital, which demonstrated that the combination of fluoxetine and rTMS led to significantly better upper limb motor outcomes than fluoxetine monotherapy or placebo in patients with hemiparesis following an ischemic stroke.
- Brand names
- Prozac
- Other names
- fluoxetine + rTMS
02
Targets
SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on fluoxetine + repetitive transcranial magnetic stimulation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluoxetine + repetitive transcranial magnetic stimulation.